云南白药: 2024年半年度报告（英文版）内容摘要

（原标题：2024年半年度报告（英文版））

2024 Interim Report of Yunnan Baiyao Group Co., Ltd.

||The reporting period|The same period of the previous year|Increase/decrease during the reporting period compared with the same period of the previous year| |-|-|-|-| |Operating revenue(RMB)|20,455,286,287.52|20,309,372,850.07|0.72%| |Net profit attributable to shareholders of the listed company(RMB)|3,188,829,903.10|2,828,011,615.30|12.76%| |Net profit attributable to shareholders of the listed company after deducting non-recurring profits and losses(RMB)|3,135,015,340.93|2,737,055,785.90|14.54%| |Net cash flows from operating activities (RMB)|3,261,617,391.99|2,251,951,370.10|44.84%| |Basic earnings per share(RMB/share)|1.79|1.58|13.29%| |Diluted earnings per share(RMB/share)|1.79|1.58|13.29%| |Weighted average ROE|7.93%|7.17%|Up 0.76 percentage points| |Total assets(RMB)|54,367,545,232.24|53,784,293,183.93|1.08%| |Net assets attributable to shareholders of the listed company(RMB)|39,369,278,205.03|39,879,122,031.51|-1.28%|